Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HMPL-A830 · 1 trial · 1 indication
Number of Participants With of DLTs
The number of participants with Adverse Events and Treatment-Related Adverse Events as Assessed by CTCAE v6.0
Assessed by investigators according to RECIST 1.1
The RP2D or RP3D will be selected by evaluating all available data from the following criteria under consideration: Determination of MTD achieved during the dose escalation part; Safety data obtained across all different doses tested; Tolerability data; PK data; efficacy data.
| Arm | Type | Description |
|---|---|---|
| Part A (Dose Escalation) | EXPERIMENTAL | - |
| Part B (Dose Optimization) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| HMPL-A830 | DRUG | Enrolled participants with solid tumors will receive HMPL-A830 treatment in a dose escalation setting at 6 predefined dose levels |
Inclusion Criteria: 1. Understood this study and are able to voluntarily sign the informed consent form (ICF); 2. Male or Female, Age ≥ 18 years; 3. Histological confirmed, unresectable, advanced or metastatic solid tumor 4. Participants must have at least one measurable lesion per Response Evaluat...
HMPL-A830 is an investigational small molecule oncology drug being developed by HUTCHMED (China) Limited for the treatment of adult solid tumors. It is in Phase 1 clinical development and has not been approved for any indication. It is designed to target EGFR and KRAS.
HMPL-A830 is being studied for the treatment of adult solid tumors. It is an investigational therapy in Phase 1 development and is not approved for any use. Its only registered trial enrolls adults aged 18 years and older with solid tumors.
HMPL-A830 targets EGFR and KRAS. It is a small molecule designed to act on these targets in adult solid tumors. Targeting EGFR and KRAS places it among therapies aimed at well-characterized oncogenic signaling pathways in solid tumor treatment.
HMPL-A830 is being developed by HUTCHMED (China) Limited, which trades under the ticker HCM. The company is running the Phase 1 program for the drug in adult solid tumors.
HMPL-A830 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulator. The Phase 1 program is evaluating the drug in adult patients with solid tumors.
HMPL-A830 is being evaluated in one Phase 1 trial, NCT07718581, titled HMPL-A830 in Solid Tumors. The trial is not yet recruiting, is controlled, enrolls 147 participants, and is being conducted in China in adults aged 18 years and older.